Key facts
- This page summarizes Eli Casdin's Form 4 filing for Tenaya Therapeutics, Inc. (TNYA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2022, 20:45.
Eli Casdin - 10 Jun 2022 Form 4 Insider Report for Tenaya Therapeutics, Inc. (TNYA)
- Reporting relationship
- Director
- Issuer ticker
- TNYA
- Reported as of
- 10 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2022, 20:45:05 UTC
- Prior SEC filing
- 10 Jun 2022
- Next SEC filing
- 17 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Drimmer Rokovich, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eli Casdin filed Form 4 for Tenaya Therapeutics, Inc. (TNYA) on 13 Jun 2022.
Change
- Previous filing in this sequence was filed on 10 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TNYA
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +39,727
- Change %
- Price
- $0.000000
- Shares after
- 39,727
- Date
- 10 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,727
- Exercise price
- $5.26
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.